Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024)

Allogene Therapeutics' FCF Margin history spans 4 years, with the latest figure at 254122.73% for Q1 2024.

  • For Q1 2024, FCF Margin fell 2854273.0% year-over-year to 254122.73%; the TTM value through Dec 2024 reached 913609.09%, down 70735995.0%, while the annual FY2024 figure was 913609.09%, 66176804.0% down from the prior year.
  • FCF Margin for Q1 2024 was 254122.73% at Allogene Therapeutics, up from 256609.52% in the prior quarter.
  • Across five years, FCF Margin topped out at 61.03% in Q4 2021 and bottomed at 1594700.0% in Q4 2022.
  • The 4-year median for FCF Margin is 177325.93% (2022), against an average of 259413.95%.
  • The largest annual shift saw FCF Margin plummeted -159463897bps in 2022 before it surged 133809048bps in 2023.
  • A 4-year view of FCF Margin shows it stood at 61.03% in 2021, then crashed by -2612753bps to 1594700.0% in 2022, then skyrocketed by 84bps to 256609.52% in 2023, then increased by 1bps to 254122.73% in 2024.
  • Per Business Quant, the three most recent readings for ALLO's FCF Margin are 254122.73% (Q1 2024), 256609.52% (Q4 2023), and 129167.44% (Q3 2023).